Telix Pharmaceuticals Begins Trading on Nasdaq
Telix Pharmaceuticals Limited, a biopharmaceutical company, has taken a significant step by launching its American Depository Shares (ADSs) on the Nasdaq Global Select Market. Trading under the ticker symbol 'TLX', this move signifies an important milestone for the company, expanding its reach to U.S. and global investors.
Enhancing Global Presence
Remaining headquartered in Australia, Telix continues to retain its primary listing on the Australian Securities Exchange (ASX). The addition of the Nasdaq listing for its ADSs is poised to complement its ASX position, thereby connecting the company with a wider range of investors.
Share Transition and Initial Trading
It’s worth noting that each ADS represents one fully paid ordinary share of Telix. There will be no new shares issued as part of this listing. Initially, the trading of these ADSs may encounter some limitations as current shareholders transition their existing TLX shares to the new form as ADSs.
Role of JPMorgan Chase
JPMorgan Chase Bank has been appointed as the depositary, custodian, and registrar for the ADS program, ensuring a smooth operational transition and management of transactions.
Leadership Insight on Nasdaq Listing
Dr. Christian Behrenbruch, Managing Director and Group Chief Executive Officer of Telix, expressed enthusiasm about this milestone. He stated that the Nasdaq listing will considerably streamline access to Telix shares for a broader portion of its workforce and investors globally. Given Telix's growth trajectory and its leadership position in the field of radiopharmaceuticals, this strategic decision is expected to bolster its presence in the North American market.
About Telix Pharmaceuticals Limited
Telix is committed to developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical devices. With operations not just limited to Australia but also extending to regions including the United States, Europe, and Japan, Telix’s product portfolio is geared towards addressing critical unmet medical needs, particularly in oncology and rare diseases.
Investor Relations Contact Information
For inquiries related to investor relations, Ms. Kyahn Williamson can be contacted via email. Similarly, Lisa Wilson with In-Site Communications represents the United States arm of the company's communications strategy.
Future Directions and Growth
The listing on Nasdaq marks a pivotal moment for Telix Pharmaceuticals as it aims to enhance visibility and engagement with investors. As Telix continues to advance its product candidates through clinical trials and research initiatives, it remains dedicated to ensuring continual innovation in the biopharmaceutical landscape.
Frequently Asked Questions
What is Telix Pharmaceuticals known for?
Telix Pharmaceuticals specializes in the development of therapeutic and diagnostic radiopharmaceuticals aimed at addressing unmet medical needs, particularly in oncology.
When did Telix begin trading on Nasdaq?
Telix began trading its American Depository Shares on Nasdaq recently, under the ticker symbol 'TLX'.
What is the significance of ADSs?
ADSs provide an opportunity for non-U.S. investors to trade shares of Telix on the Nasdaq, facilitating easier access to the company’s stock.
Who is involved in the Nasdaq listing?
JPMorgan Chase Bank is the depositary, custodian, and registrar for the ADS program, overseeing the operational aspects of the trade.
How can investors reach Telix for inquiries?
Investors can reach out to Telix’s investor relations via the provided emails for further information and inquiries.
